Join to view full profile
800 Rose StreetLexington, KY 40536
Phone+1 859-323-7507
Fax+1 859-257-7715
Dr. Hao is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
Atrium Health Navicent The Medical Center/Mercer University School of MedicineResidency, Internal Medicine, 2004 - 2007- OtherClass of 1986
Certifications & Licensure
KY State Medical License 2017 - 2027
GA State Medical License 2009 - 2019
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Pembrolizumab + Idelalisib for Lung Cancer Study Start of enrollment: 2017 Sep 26
Publications & Presentations
PubMed
- EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming.Avery R Childress, Dave-Preston Esoe, Xiulong Song, Christain M Gosser, Yindan Lin
Biorxiv. 2026-08-01 - Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.Lauren S Yeager, Ralph G Zinner, Zhonglin Hao
Cureus. 2026-06-01 - Mental Health Needs of Families of Patients in Intensive Care Units and the Role of Mobile Health: Survey Study.Anthony Faiola, Saira Soroya, Zhonglin Hao, Reinhold Munker
JMIR Formative Research. 2026-03-20
Press Mentions
UK First in Nation to Treat Small Cell Lung Cancer Patient with New ImmunotherapyJanuary 5th, 2026- First US Patient Treated with New Lung Cancer TherapyJanuary 22nd, 2026
- Cancer Death Rates Have Hit a 30-Year Low. Here’s How We Got There | OpinionJune 27th, 2026
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
